Darunavir

ARV U.S. Brand Name

Prezista

ARV Abbreviation(s)

DRV

U.S. FDA Label

Darunavir Labeling (Package Insert)

ARV Class

Protease Inhibitors

First U.S. Approval

December 16, 2011

U.S. Manufacturer

Janssen

Formulations

Strength	Formulation	Image	Description	Boosted
DRV 800 mg, COBI 150 mg	Film-Coated Tablets	X	Pink, oval-shaped, film-coated tablets debossed with "800" on one side and "TG" on the other side	Yes
800 mg	Film-Coated Tablets	X	Dark red oval tablet with imprint of 800 on one side and T on the other	No
600 mg	Film-Coated Tablets	X	Orange oval tablet with imprint of 600MG on one side and TMC on the other.	No
150 mg	Film-Coated Tablets	X	White oval tablet with imprint of 150 one side and TMC on the other.	No
75 mg	Film-Coated Tablets	X	White oval tablet with imprint of 75 on one side and TMC on the other.	No
100 mg in 1 mL	Oral Suspension	X	White to off-white strawberry-flavored solution, 200 mL/bottle	No

Generic Available?

Other Reference Links

National HIV Curriculum

U.S. Guidelines Links

Clinical Info Drug Database

FDCs

Darunavir / Cobicistat

Darunavir / Cobicistat / Emtricitabine / Tenofovir alafenamide

Assistance Programs

Janssen Care Path

Displaying 101 - 186 of 186

	Interaction Color Code	Clinical Bottom Line	Clinical Effects	Drug 1 effect	Drug 2 dose	Drug 2 effect	Management
Darunavir Alfuzosin 934	Red: Avoid combination	Do not coadminister: Potential for increased levels of alfuzosin	Potential for increased risk of alfuzosin adverse effects (e.g. hypotension)				Contraindicated. Use alternative agents.
Darunavir Ivabradine 933	Red: Avoid combination	Do not coadminister: Potential for increased ivabradine levels	Potential for increased risk of ivabradine adverse effects (e.g. prolonged QT, cardiac arrythmias)				Use alternative agents
Darunavir Irinotecan 932	Red: Avoid combination	Do not coadminister: Potential for increased irinotecan levels	Potential for increased risk of irinotecan adverse effects				Discontinue DRV / c at least 1wk prior to starting irinotecan. Do not coadminister unless there are no therapeutic alternatives
Darunavir G/P 931	Red: Avoid combination	Do not coadminister: Potential for increased glecaprevir / pibrentasvir levels	Potential for increased glecaprevir / pibrentasvir adverse effects				Use alternative agents
Darunavir Flibanserin 930	Red: Avoid combination	Do not coadminister: Potential for increased flibanserin levels	Potential for increased risk of flibanserin adverse effects				Contraindicated. Use alternative agents.
Darunavir Everolimus 929	Red: Avoid combination	Do not coadminister: Potential for increased everolimus levels	Potential for increased risk of everolimus adverse effects	Not studied		Not studied (may increase everolimus levels)	Use alternative agents
Darunavir Eplerenone 928	Red: Avoid combination	Do not coadminister: Potential for increased eplerenone levels	Potential for increased risk of eplerenone adverse effects				Contraindicated. Use alternative agents.
Darunavir Dronedarone 927	Red: Avoid combination	Do not coadminister: Potential for increased dronedarone levels	Potential for increased risk of dronedarone adverse effects				Use alternative agents
Darunavir Dihydroergotamine 926	Red: Avoid combination	Do not coadminister: Potential for increased dihydroergotamine levels	Potential for increased risk of dihydroergotamine adverse effects (e.g. peripheral vasospasm, ischemia)				Contraindicated. Use alternative agents.
Darunavir Bedaquiline 925	Red: Avoid combination	Do not coadminister: Potential for increased bedaquiline levels	Potential for increased risk of bedaquiline adverse effects				Avoid combination and use alternative agents. If coadministering, monitor liver function and QTc interval
Darunavir Avanafil 924	Red: Avoid combination	Do not coadminister: Potential for increased avanafil levels	Potential for increased risk of avanafil adverse effects				Use alternative agents
Darunavir RPT 923	Red: Avoid combination	Do not coadminister: Potential for decreased darunavir levels	Potential loss of antiviral efficacy				Use alternative agents
Darunavir Clopidogrel 922	Red: Avoid combination	Do not coadminister: Potential for decreased clopidogrel levels	Potential for increased bleeding risk				Use alternative agents
Darunavir Propafenone 921	Red: Avoid combination	Do not coadminister: Increased levels of propafenone	Potential for increased risk of propafenone adverse effects				Use alternative agents
Darunavir EBR/GZR 920	Red: Avoid combination	Do not coadminister: Increased levels of grazoprevir	Potential for increased risk of ALT elevations due to a significant increase in grazoprevir plasma concentrations caused by OATP1B1 / 3 inhibition	No significant change	50 / 100 mg once daily	Elbasvir AUC increase 66%; Grazoprevir AUC increase 7.5 fold	Contraindicated. Use alternative agents.
Darunavir Flecainide 919	Red: Avoid combination	Do not coadminister: Increased levels of flecainide	Potential for increased risk of flecainide adverse effects				Use alternative agents
Darunavir Z-Pak 918	Green: Administer standard doses	Administer standard doses
Darunavir ETR 917	Green: Administer standard doses	Administer standard doses			200 mg twice daily
Darunavir SOF/VEL 916	Green: Administer standard doses	Administer standard doses		Cmax decrease 10%, AUC decrease 8%, Cmin decrease 13%.	400 / 100 mg	Sofosbuvir Cmax decrease 38%, AUC decrease 28%; Velpatasvir Cmax decrease 24%, AUC decrease 16%.
Darunavir Omeprazole 915	Green: Administer standard doses	Administer standard doses		No significant change	20 mg once daily	Not reported
Darunavir Ranitidine 914	Green: Administer standard doses	Administer standard doses		No significant change	150 mg BID	Not reported
Darunavir LDV/SOF 913	Green: Administer standard doses	Administer standard doses		No significant change	90 / 400 mg once daily	Ledipasvir Cmax increase 45%, AUC increase 39%, Cmin increase 39%; Sofosbuvir Cmax increase 45%, AUC increase 34%
Darunavir SOF 912	Green: Administer standard doses	Administer standard doses		No significant change	400 mg x 1	Cmax increase 45%, AUC increase 34%
Darunavir TDF 911	Green: Administer standard doses	Administer standard doses		Cmax increase 16%, AUC increase 21%, Cmin increase 24%	300 mg once daily	Cmax increase 24%, AUC increase 22%, Cmin increase 37%
Darunavir NVP 910	Green: Administer standard doses	Administer standard doses		Cmax increase 40%, AUC increase 24%, Cmin increase 2%	200 mg BID	Cmax increase 18%, AUC increase 27%, Cmin increase 47%
Darunavir EFV 909	Green: Administer standard doses	Administer standard doses		Cmax decrease 15%, AUC decrease 13%, Cmin decrease 31%	600 mg once daily	Cmax increase 15%, AUC increase 21%, Cmin increase 17%
Darunavir ETR 908	Green: Administer standard doses	Administer standard doses		Not reported	100 mg BID	Cmax decrease 32%, AUC decrease 37%, Cmin decrease 49%
Darunavir DTG 907	Green: Administer standard doses	Administer standard doses		No significant change	30 mg once daily	Cmax decrease 11%, AUC decrease 22%, Cmin decrease 38%
Darunavir ATV 906	Green: Administer standard doses	Administer standard doses		No significant change	300 mg once daily	Cmax decrease 11%, AUC increase 8%, Cmin increase 52%
Darunavir Pitavastatin 905	Green: Administer standard doses	Administer standard doses		No significant change	4 mg once daily	AUC decreased 26%
Darunavir RPV 904	Green: Administer standard doses	Administer standard doses	Potential for increased rilpivirine adverse effects	No significant change	150 mg once daily	Cmax decrease 21%, AUC increase 130%, Cmin increase 178%
Darunavir Beclomethasone 903	Green: Administer standard doses	Administer standard doses		Not reported	160 mcg inhaled BID	No change in AUC of active metabolite	Use lowest possible dose and titrate to effect
Darunavir Daclatasvir 902	Green: Administer standard doses	Administer standard doses		No significant change	30 mg once daily	No significant change	No dose adjustment necessary
Darunavir Edoxaban 901	Green: Administer standard doses	Administer standard doses					No dose adjustment if CrCL < 50 ml / min. Avoid concomitant use if CrCl > 50ml / min.
Darunavir Dabigatran 900	Green: Administer standard doses	Administer standard doses					No dose adjustment if CrCL < 50 ml / min. Avoid concomitant use if CrCl > 50ml / min.
Darunavir Warfarin 899	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of warfarin	Decreased warfarin effects (e.g. decreased INR, increased risk of clotting)	Not reported	10 mg x 1	S-warfarin Cmax decrease 8%, AUC decrease 21%	If coadministering, monitor INR and adjust warfarin as indicated. Monitor for signs and symptons of bleeding.
Darunavir Sertraline 898	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of sertraline	Potential decreased sertraline effects	No significant change	50 mg once daily	Cmax decrease 44%, AUC decrease 49%, Cmin decrease 49%	Titrate sertraline to effect; monitor to ensure continued response if darunavir / ritonavir initiated
Darunavir Paroxetine 897	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of paroxetine	Potential decreased paroxetine effects	No significant change	20 mg once daily	Cmax decrease 36%, AUC decrease 39%, Cmin decrease 37%	Titrate paroxetine to effect; monitor for continued antidepressant response if darunavir / ritonavir initiated
Darunavir Methadone 896	Yellow: Adjust dosing	Adjust dosing to avoid reduced levels of methadone	May decrease methadone effects (e.g. withdrawal)	Not reported	55-200 mg once daily (stable dose)	R-methadone: Cmax decrease 24%, AUC decrease 16%, Cmin decrease 15%; S-methadone: Cmax decrease 44%, AUC decrease 36%, Cmin decrease 40%	If coadministering monitor for signs and symptoms of methadone withdrawal. Some patients may require an increased methadone dose
Darunavir Solifenacin 895	Yellow: Adjust dosing	Adjust dosing to avoid increased solifenacin levels	Potential for increased risk of zolpidem adverse effects				If coadministering, do not exceed solifenacin 5 mg once daily
Darunavir Saxagliptin 894	Yellow: Adjust dosing	Adjust dosing to avoid increased saxagliptin levels	Potential for increased saxagliptin adverse effects				If coadministering, do not exceed saxagliptin dose of 2.5 mg once daily
Darunavir Pimavanserin 893	Yellow: Adjust dosing	Adjust dosing to avoid increased pimavanserin levels	Potential for increased risk of pimavanserin adverse effects				If coadministering, decrease dose of pimavanserin to 10 mg once daily
Darunavir Vardenafil 892	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of vardenafil	Increased risk of vardenafil adverse effects (e.g. hypotension, priapism)				Do not exceed 2.5 mg dose in 72 hours
Darunavir Thioridazine 891	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of thioridazine	Potential for increased risk of thioridazine adverse effects				If coadministering, dose reduction may be necessary
Darunavir Tadalafil 890	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of tadalafil	Increased risk of tadalafil adverse effects (e.g. hypotension, priapism)	Not studied		Not studied (may increase tadalafil levels)	For erectile dysfunction, initiate tadalafil 5 mg dose and do not exceed 10 mg every 72 hours. Monitor adverse effects. For patients taking a protease inhibitor (stable > 7 days) requiring tadalafil for pulmonary arterial hypertension, initiate 20 mg once daily and increase to 40 mg once daily based on tolerability. Patients currently on tadalafil who require a PI should stop tadalafil ³24 hours before PI initiation, take the PI for 7 days, then resume tadalafil at 20 mg. Maximum recommended daily dose for treatment of BPH is 2.5 mg daily.
Darunavir Sildenafil 889	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of sildenafil. (Do not coadminister for pulmonary hypertension)	Increased risk of sildenafil adverse effects (e.g. hypotension, priapism)	Not reported	25 mg x 1	Cmax decrease 38% (compared to sildenafil 100 mg x 1 without darunavir / ritonavir)	For erectile dysfunction, do not exceed sildenafil 25 mg every 48 hours and monitor for adverse effects. Contraindicated if using sildenafil for pulmonary arterial hypertension.
Darunavir Rosuvastatin 888	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of rosuvastatin	Increased risk of rosuvastatin adverse effects (e.g. myopathy, rhabdomyolysis); No change in lipid lowering ability within 35 day study period	No significant change	10 mg once daily	Cmax increase 144%,AUC increase 48%	Consider using alternative agents. If coadministering, consider initiating low dose rosuvastatin 5 mg daily
Darunavir Risperidone 887	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of risperidone	Potential for increased risk of risperidone adverse effects				If coadministering, dose reduction may be necessary
Darunavir RFB 886	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of rifabutin	Increased darunavir and rifabutin effects. Note that lower rifabutin exposure has been reported in HIV- infected patients as compared to healthy study participants.	Darunavir Cmax increase 42%, AUC increase 57%, Cmin increase 75%; Ritonavir Cmax increase 68%, AUC increase 66%, Cmin increase 31%	150 mg every other day	Rifabutin: Cmax decrease 28%, AUC decrease 7%, Cmin increase 64%; 25-O-desacetylrifabutin: Cmax increase 377%, AUC increase 881%, Cmin increase 2610%	Dose reduction of RFB by 75% of usual dose is recommended, such as rifabutin 150 mg every other day. Monitor for antimycobacterial activity and adverse events. Consider therapeutic drug monitoring.
Darunavir Pravastatin 885	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of pravastatin	Increased risk of pravastatin adverse effects (e.g. myopathy, rhabdomyolysis)	Not studied	40 mg x 1	Cmax increase 63%, AUC increase 81%	Use lowest possible starting dose, monitor for toxicity and titrate.
Darunavir MVC 884	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Potential for increased maraviroc adverse effects	Not reported	150 mg BID	Cmax increase 77%, AUC increase 210%, Cmin increase 427%	Use maraviroc 150 mg BID when combined with darunavir / ritonavir
Darunavir MVC 883	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Potential for increased maraviroc adverse effects	Not reported	150 mg BID	Cmax increase 129%, AUC increase 305%, Cmin increase 700%	Use maraviroc 150 mg BID when combined with darunavir / ritonavir
Darunavir Digoxin 882	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of digoxin	Increased risk of digoxin adverse effects	Not reported	0.4 mg x 1	Cmax increase 15%, AUC increase 36%	Initiate lowest dose digoxin and titrate to desired clinical effect
Darunavir Colchicine 881	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of colchicine	Increased risk of colchicine adverse effects				For treatment of gout, reduce colchicine dosage to 0.6 mg x 1 then 0.3 mg one hour later. Dose should not be repeated earlier than 3 days after. For gout prophylaxis, reduce colchicine dose to 0.3 mg daily if on 0.6 mg BID prior to PI therapy or reduce colchicine dose to 0.3 mg every other day if on 0.6 mg daily prior to PI therapy. For treatment of familial Mediterranean fever do not exceed colchicine 0.6 mg once daily or 0.3 mg BID. Do not coadminister in patients with hepatic or renal impairment.
Darunavir Clarithromycin 880	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of clarithromycin	Increased risk of antibacterial adverse effects	Cmax decrease 17%, AUC decrease 13%, Cmin increase 1%	500 mg BID	Cmax increase 26%, AUC increased 57%, Cmin increase 174%	In patients with CrCl 30-60 mL / min, reduce dose of clarithromycin by 50%. In patients with CrCl <30 mL / min, reduce clarithromycin dose by 75%. Monitor for clarithromycin-related toxicities and / or consider alternative macrolide.
Darunavir Brexpiprazole 879	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of brexpiprazole	Potential for increased risk of brexpiprazole adverse effects				Administer 25% of the usual brexpiprazole dose. Titrate dose based on clinical monitoring for efficacy / adverse events.
Darunavir Bosentan 878	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of bosentan	Potential for increased risk of bosentan adverse effects				Start low and titrate bosentan to effect. If patient has been on protease inhibitor (other than unboosted atazanavir) for more than 10 days, start bosentan at 62.5 mg daily or every other day. If patient is currently on bosentan and requires a PI (other than unboosted atazanavir), stop bosentan for at least 36 hours prior to initiating ART. Wait 10 days and then resume bosentan starting with 62.5 mg daily or every other day.
Darunavir Aripiprazole 877	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of aripiprazole	Potential for increased risk of aripiprazole adverse effects				Administer 25% of the usual aripiprazole dose. Titrate dose based on clinical monitoring for efficacy / adverse events.
Darunavir Iloperidone 876	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of iloperidone	Potential for increased risk of iloperidone adverse effects				If coadministering, decrease dose of iloperidone by 50%
Darunavir Fluvastatin 875	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of fluvastatin	Potential for increased risk of fluvastatin adverse effects				Consider using alternative agents. If coadministering, initate lowest recommended dose and titrate while monitoring
Darunavir Fesoterodine 874	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of fesoterodine	Potential for increased risk of zolpidem adverse effects				If coadministering, do not exceed fesoterodine 4 mg once daily
Darunavir Cariprazine 873	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of cariprazine	Potential for increased risk of cariprazine adverse effects				If starting cariprazine in a patient on a protease inhibitor, administer cariprazine 1.5 mg on Day 1 and Day 3, with no dose given on Day 2. From Day 4 onward, administer cariprazine 1.5 mg daily. Dose may be increased to a maximum of cariprazine 3 mg daily. If starting a protease inhibitor for a patient already taking cariprazine 3-6mg, reduce dose by half. For patients taking cariprazine 4.5 mg daily, reduced cariprazine dose to 1.5 - 3 mg daily. For patients taking cariprazine 1.5 mg daily, reduce to cariprazine 1.5 mg every other day. If PI is withdrawn, cariprazine dose may need to be increased.
Darunavir Calcifediol 872	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of calcifediol	Potential for increased risk of calcifediol adverse effects				If coadministering, dose adjustment may be required. Monitor serum 25-hydroxyvitamin D, intact PTH, and serum calcium concentrations
Darunavir Atorvastatin 871	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of atorvastatin	Increased risk of atorvastatin adverse effects (e.g. myopathy, rhabdomyolysis)	Not reported	40 mg once daily on days 1-4, then 10 mg once daily on days 4-7	Cmax decrease 44%, AUC decrease 15%, Cmin increase 81% (10 mg daily with darunavir / ritonavir compared to atorvastatin 40 mg daily alone)	Consider using alternative agents. If coadministering, consider low dose atorvastatin and doses < 20 mg. Monitor for myopathy
Darunavir Valproic Acid 870	Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of valproic acid	Potential for decreased anticonvulsant effects				Monitor anticonvulsant level and adjust accordingly
Darunavir Omeprazole 869	Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of omeprazole	Potential decreased omeprazole efficacy	No significant change	40 mg x 1	Cmax decrease 34%, AUC decrease 42%	Consider using alternative agents. If coadministering, monitor for omeprazole efficacy. If no symptomatic relief, increase dose to no more than 40 mg once daily
Darunavir Lamotrigine 868	Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of lamotrigine	Potential for decreased anticonvulsant effects				Monitor anticonvulsant level and adjust accordingly
Darunavir Canagliflozin 867	Yellow: Adjust dosing	Adjust dosing to avoid decreased levels of canagliflozin	Potential for decreased glucose lowering effect				If a patient is already tolerating canagliflozin 100 mg daily, increase canagliflozin dose to 200 mg daily. If a patient is already tolerating canagliflozin 200 mg daily and requires additional glycemic control, management strategy is based on renal function, 300 mg if eGFR>60 or add another agent if eGFR<60
Darunavir Buprenorphine / naloxone 866	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of buprenorphine / naloxone	Potential for increased buprenorphine / naloxone effects	Not studied	8-16 / 2-4 mg	Norbuprenorphine: Cmax increase 36%, AUC increase 46%, Cmin increase 71%	If initiating buprenorphine / naloxone in patients taking DRV / r or DRV / c, carefully titrate dose to desired effect
Atazanavir DRV 754	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of antiretrovirals		Atazanavir Cmin increased 52%	400 mg BID with ritonavir 100 mg BID	No significant change	If used in combination, atazanavir may be given in conjunction with darunavir / ritonavir at study doses (300mg daily plus 400 / 100 mg daily)
Tenofovir disoproxil fumarate DRV 752	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased risk of TDF and / or darunavir adverse effects	Cmax increase 24%, AUC increase 22%, Cmin increase 37%	300 mg BID with ritonavir 100 mg BID	Cmax increase 16%, AUC increase 21%, Cmin increase 24%	If coadministering, monitor for TDF adverse effects (e.g. renal function decline)
Tenofovir alafenamide DRV/c 707	Green: Administer standard doses	Administer standard doses		Cmax decreased 7%, AUC decreased 2%	800 / 150 mg once daily	Cmax increased 2%, AUC decreased 1%, Cmin decreased 3%
Tenofovir alafenamide DRV/r 702	Green: Administer standard doses	Administer standard doses		Cmax increased 42%, AUC increased 6%	800 / 100 mg once daily	Cmax decreased 1%, AUC increased 1%, Cmin increased 13%
Nevirapine DRV 639	Orange: Minimal data to guide interaction	Minimal data to guide interaction: weigh risks and benefits of using this combination	Increased Nevirapine effects, increased risk of hepatotoxcity	AUC increased 110%			Use alternative agents
Nevirapine DRV 597	Green: Administer standard doses	Administer standard doses	Potential for increased darunavir effects; Potential for increased nevirapine effects	Nevirapine AUC increased 110%; Cmax increased 115%; Cmin increased 135%; half-live: decreased 52% (data compared to historical controls)	400 mg BID with ritonavir 100 mg BID	Darunavir AUC increased 24%; Cmax increased 40%
Etravirine DRV 529	Green: Administer standard doses	Administer standard doses		Etravirine AUC increased 80%; Cmax increased 81%; Cmin increased 67% (compared to etravirine 100 mg BID)		Darunavir AUC increased 15%
Etravirine DRV 528	Green: Administer standard doses	Administer standard doses		Etravirine AUC decreased 37%; Cmax decreased 32%; Cmin decreased 49%	600 mg BID with 100 mg ritonavir BID	No significant change
Efavirenz DRV 396	Green: Administer standard doses	Administer standard doses	Potential for increased efavirenz effects	Efavirenz AUC increased 21%; Cmin increased 17%	300 mg BID with ritonavir 100 mg BID	Darunavir Cmin decreased 31%; Cmax decreased 15%; AUC decreased 13%	Monitor for increased risk of efavirenz related side effects. Consider monitoring drug levels
Raltegravir DRV 315	Green: Administer standard doses	Administer standard doses		Raltegravir AUC decreased 29%; Cmin increased 38%; Cmax decreased 33%	600 mg Q12H with 100 mg ritonavir Q12H
Dolutegravir DRV/r 111	Green: Administer standard doses	Administer standard doses		Cmax decreased 11%, AUC decreased 22%, Cmin decreased 38%	600 / 100 mg once daily	Not studied
Dolutegravir ETR + DRV/r 106	Green: Administer standard doses	Administer standard doses		Cmax decreased 12%, AUC decreased 25%, Cmin decreased 37%	200 mg + 600 / 100 mg BID	Not studied
Maraviroc DRV 49	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc		Maraviroc Cmin increased 16%; Cmax no significant change (when compared to maraviroc 300 mg BID without darunavir / ritonavir in separate control arm)	800 / 100 mg BID	Not reported	Reduce dose of maraviroc to 150 mg BID
Maraviroc DRV/r 46	Yellow: Adjust dosing	Adjust dosing to avoid increased levels of maraviroc	Potential maraviroc-associated adverse effects	Maraviroc AUC increased 305%; Cmax increased 129%	600 mg / 100 mg BID	Not reported	Reduce dose of maraviroc to 150 mg BID
Fostemsavir DRV/r + ETR 8	Green: Administer standard doses	Administer standard doses		Temsavir Cmax increased 53%, AUC increased 34%, Cmin increased 33%	DRV 600mg twice daily, / r 100mg twice daily, ETR 200mg twice daily	DRV and ritonavir no significant changes. Etravirine Cmax increased 18%, AUC increased 28%, Cmin increased 28%.
Fostemsavir DRV/r 7	Green: Administer standard doses	Administer standard doses		Temsavir Cmax increased 52%, AUC increased 63%, Cmin increased 88%	DRV 600mg twice daily, / r 100mg twice daily	DRV no significant change. Ritonavir AUC increased 15%, Cmin increased 19%
Darunavir

Subscribe to Darunavir